☆ 4.6 Letter Publication with Expression of Concern

Sacubitril/valsartan in PARADIGM-HF (Publication with Expression of Concern. See vol. 7, pg. 250, 2019) (Publication with Expression of Concern. See vol. 7, pg. 250, 2019)

LANCET DIABETES & ENDOCRINOLOGY (2017)

Get Full Text
Add to Collection

Journal

LANCET DIABETES & ENDOCRINOLOGY
Volume 5, Issue 7, Pages 495-496

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S2213-8587(17)30177-8

Keywords

-

Categories

Endocrinology & Metabolism

Funding

  1. Novartis
  2. Servier
  3. Vifor

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.